# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Peeling Skin Syndrome is a rare autosomal disease with no approved treatment or cure Initial clinical site and pediatric pat...
Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate ...
-SEC Filing
Maxim Group analyst Naz Rahman maintains Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy and lowers the price target from $15...